Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.40 |
| ▸ | MAOB | P27338 | 8/20 | 0.40 |
| ▸ | KDM1A | O60341 | 7/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7894379 | 0.84 | MAOA (0.37) | MAOAMAOBKDM1AHSD11B1 | |
| SCHEMBL9120691 | 0.77 | MAOA (0.46) | MAOAMAOBKDM1ARCOR1HSD11B1 | |
| SCHEMBL9325850 | 0.77 | — | — | |
| SCHEMBL8838229 | 0.76 | SLC7A5 (0.44) | HSD11B1 | |
| SCHEMBL17414858 | 0.75 | MAOA (0.47) | MAOAMAOBKDM1ALOXL2RCOR1 | |
| SCHEMBL29274276 | 0.74 | SIGMAR1 (0.41) | KDM1ASMN1; SMN2 | |
| SCHEMBL11663054 | 0.74 | — | — | |
| SCHEMBL9530330 | 0.72 | LTA4H (0.39) | — | |
| SCHEMBL8155755 | 0.71 | MAOA (0.38) | MAOAMAOBKDM1AHSD11B1 | |
| SCHEMBL8907133 | 0.71 | MAOA (0.38) | MAOAMAOBKDM1AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003062257-A1 | DEAZAPURINE NUCLEOSIDE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS | RIBAPHARM INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003061576-A2 | DEAZAPURINE NUCLEOSIDE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS | RIBAPHARM INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| US-20020051991-A1 | Rapid generation of diverse nucleoside and nucleotide libraries | HONG ZHI (US) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020051991-A1 | Rapid generation of diverse nucleoside and nucleotide libraries | PNP, ADAR, SAMHD1 | MAOA 2537/4885MAOB 1867/4885KDM1A 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.